U.S.S.N. 10/028,547
Filed: December 19, 2001
Clean Version of Amended Claims

Clean Version of Amended Claims

Pursuant to 37 C.F.R. § 1.121(c)(1)(ii)

1. (Three times Amended) A method of treating fibromyalgia syndrome (FMS) comprising administering to an animal subject suffering from FMS, a composition wherein the active ingredient consists of milnacipran, or a pharmaceutically acceptable salt thereof in an amount effective to treat the chronic pain and fatigue associated with FMS.

Claims 2-6 are cancelled.

7. The method according to claim 1, wherein the animal subject is human.

8. (amended) The method according to claim 1, wherein the amount of milnacipran administered is from about 25 mg to about 400 mg per day.

9. (unamended) The method according to claim 1, wherein the milnacipran is formulated in a sustained release formulation.

Claims 10-30 are cancelled.

31. (unamended) The method of claim 1 wherein the amount of milnacipran administered is at least 100 mg per day.

32. (unamended) The method of claim 1 wherein the amount of milnacipran administered is between 100 and 400 mg per day.

33. (unamended) The method of claim 1 wherein the amount of milnacipran administered is between 100 and 250 mg per day.

ATL1 #567388 v1

CYFR 100 DIV
CLIENT/MATTER